Danaher (DHR)
Market Price (10/29/2026): $236.9 | Market Cap: $166.5 BilSector: Health Care | Industry: Life Sciences Tools & Services
Danaher (DHR)
Market Price (10/29/2026): $236.9Market Cap: $166.5 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 27%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 22%, CFO LTM is 6.9 Bil, FCF LTM is 5.7 Bil Stock buyback supportStock Buyback 3Y Total is 10.0 Bil Low stock price volatilityVol 12M is 30% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Automation & Robotics. Themes include Advanced Diagnostics, Show more. | Trading close to highsDist 52W High is -2.7% Weak multi-year price returns2Y Excs Rtn is -41%, 3Y Excs Rtn is -67% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 32x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x, P/EPrice/Earnings or Price/(Net Income) is 38x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.2% Key risksDHR key risks include [1] a heavy reliance on its acquisition-based growth strategy, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 27%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 22%, CFO LTM is 6.9 Bil, FCF LTM is 5.7 Bil |
| Stock buyback supportStock Buyback 3Y Total is 10.0 Bil |
| Low stock price volatilityVol 12M is 30% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Automation & Robotics. Themes include Advanced Diagnostics, Show more. |
| Trading close to highsDist 52W High is -2.7% |
| Weak multi-year price returns2Y Excs Rtn is -41%, 3Y Excs Rtn is -67% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 32x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x, P/EPrice/Earnings or Price/(Net Income) is 38x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.2% |
| Key risksDHR key risks include [1] a heavy reliance on its acquisition-based growth strategy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Danaher (DHR) stock has gained about 25% since 6/30/2026 because of the following key factors:
1. Strong Fiscal Q3 2026 Earnings and Raised Full-Year Guidance. Danaher reported adjusted earnings of $2.11 per share for fiscal Q3 2026, surpassing the consensus estimate of $1.92 per share by 9.9%. Revenues also came in slightly ahead of expectations at $6.6 billion, compared to the $6.56 billion forecast. Following these results, the company raised its full-year 2026 adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62, an increase from its prior outlook of $8.45 to $8.60.
2. Accelerating Core Revenue Growth Driven by Improving End Markets. Danaher saw an acceleration in its core revenue growth, excluding respiratory revenue, to 5.5% in fiscal Q3 2026, up from 4.5% in fiscal Q2 2026. This indicates improving underlying business health across its diverse portfolio. Management noted strengthening demand in key areas such as bioprocessing, where orders grew mid-teens, and in the diagnostics segment, which saw 7% core revenue growth excluding respiratory.
Show more
Danaher (DHR) stock has gained about 25% since 6/30/2026 because of the following key factors:
1. Strong Fiscal Q3 2026 Earnings and Raised Full-Year Guidance. Danaher reported adjusted earnings of $2.11 per share for fiscal Q3 2026, surpassing the consensus estimate of $1.92 per share by 9.9%. Revenues also came in slightly ahead of expectations at $6.6 billion, compared to the $6.56 billion forecast. Following these results, the company raised its full-year 2026 adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62, an increase from its prior outlook of $8.45 to $8.60.
2. Accelerating Core Revenue Growth Driven by Improving End Markets. Danaher saw an acceleration in its core revenue growth, excluding respiratory revenue, to 5.5% in fiscal Q3 2026, up from 4.5% in fiscal Q2 2026. This indicates improving underlying business health across its diverse portfolio. Management noted strengthening demand in key areas such as bioprocessing, where orders grew mid-teens, and in the diagnostics segment, which saw 7% core revenue growth excluding respiratory.
3. Positive Analyst Sentiment and Upgraded Price Targets. Leading up to and following the Q3 2026 earnings report, several financial analysts reiterated "Buy" or "Outperform" ratings and increased their price targets for Danaher. For instance, in October 2026, TD Cowen raised its price target from $236 to $255, Barclays increased its target from $230 to $255, and RBC Capital moved its target from $215 to $250. The consensus rating for Danaher remains a "Strong Buy" among analysts, with an average 12-month price target of $244.14.
4. Strategic Leadership Transition and Focus on Organic Growth. Effective October 1, 2026, Julie Sawyer Montgomery assumed the roles of President and Chief Executive Officer, and also joined Danaher's Board of Directors. The new leadership has emphasized a strategic focus on accelerating organic growth across operating units to gain market share, alongside pursuing strategic mergers and acquisitions.
5. Robust Free Cash Flow Generation. Danaher demonstrated strong financial health with significant operating and free cash flow generation in fiscal Q3 2026. The company reported operating cash flow of $1.9 billion and non-GAAP free cash flow of $1.6 billion. For the first nine months of 2026, year-to-date free cash flow reached $4 billion, representing a 128% conversion rate of net income, which underscores the quality of its earnings.
Show less
Stock Movement Drivers
Fundamental Drivers
The 23.1% change in DHR stock from 6/30/2026 to 10/28/2026 was primarily driven by a 13.6% change in the company's Net Income Margin (%).| (LTM values as of) | 6302026 | 10282026 | Change |
|---|---|---|---|
| Stock Price ($) | 190.14 | 234.07 | 23.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 24,778 | 25,608 | 3.3% |
| Net Income Margin (%) | 14.9% | 16.9% | 13.6% |
| P/E Multiple | 36.5 | 38.0 | 4.2% |
| Shares Outstanding (Mil) | 708 | 704 | 0.6% |
| Cumulative Contribution | 23.1% |
Market Drivers
6/30/2026 to 10/28/2026| Return | Correlation | |
|---|---|---|
| DHR | 23.1% | |
| Market (SPY) | 3.4% | -0.3% |
| Sector (XLV) | 13.3% | 37.4% |
Fundamental Drivers
The 23.9% change in DHR stock from 3/31/2026 to 10/28/2026 was primarily driven by a 15.0% change in the company's Net Income Margin (%).| (LTM values as of) | 3312026 | 10282026 | Change |
|---|---|---|---|
| Stock Price ($) | 188.87 | 234.07 | 23.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 24,568 | 25,608 | 4.2% |
| Net Income Margin (%) | 14.7% | 16.9% | 15.0% |
| P/E Multiple | 37.0 | 38.0 | 2.9% |
| Shares Outstanding (Mil) | 707 | 704 | 0.5% |
| Cumulative Contribution | 23.9% |
Market Drivers
3/31/2026 to 10/28/2026| Return | Correlation | |
|---|---|---|
| DHR | 23.9% | |
| Market (SPY) | 19.1% | 3.8% |
| Sector (XLV) | 23.1% | 43.1% |
Fundamental Drivers
The 18.9% change in DHR stock from 9/30/2025 to 10/28/2026 was primarily driven by a 19.0% change in the company's Net Income Margin (%).| (LTM values as of) | 9302025 | 10282026 | Change |
|---|---|---|---|
| Stock Price ($) | 196.81 | 234.07 | 18.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 24,013 | 25,608 | 6.6% |
| Net Income Margin (%) | 14.2% | 16.9% | 19.0% |
| P/E Multiple | 41.3 | 38.0 | -7.9% |
| Shares Outstanding (Mil) | 716 | 704 | 1.8% |
| Cumulative Contribution | 18.9% |
Market Drivers
9/30/2025 to 10/28/2026| Return | Correlation | |
|---|---|---|
| DHR | 18.9% | |
| Market (SPY) | 16.9% | 17.6% |
| Sector (XLV) | 30.8% | 49.4% |
Fundamental Drivers
The 8.2% change in DHR stock from 9/30/2023 to 10/28/2026 was primarily driven by a 51.7% change in the company's P/E Multiple.| (LTM values as of) | 9302023 | 10282026 | Change |
|---|---|---|---|
| Stock Price ($) | 216.29 | 234.07 | 8.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 23,065 | 25,608 | 11.0% |
| Net Income Margin (%) | 27.6% | 16.9% | -38.7% |
| P/E Multiple | 25.1 | 38.0 | 51.7% |
| Shares Outstanding (Mil) | 737 | 704 | 4.8% |
| Cumulative Contribution | 8.2% |
Market Drivers
9/30/2023 to 10/28/2026| Return | Correlation | |
|---|---|---|
| DHR | 8.2% | |
| Market (SPY) | 86.9% | 40.3% |
| Sector (XLV) | 46.2% | 58.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DHR Return | 49% | -19% | -1% | -0% | 0% | 2% | 21% |
| Peers Return | 23% | -17% | -8% | -1% | 2% | 36% | 28% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| DHR Win Rate | 83% | 33% | 50% | 42% | 42% | 60% | |
| Peers Win Rate | 67% | 42% | 47% | 50% | 53% | 62% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DHR Max Drawdown | -14% | -28% | -25% | -19% | -30% | -33% | |
| Peers Max Drawdown | -19% | -33% | -33% | -19% | -34% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, A, ABT, BDX, ILMN. See DHR Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/28/2026 (YTD)
How Low Can It Go
| Event | DHR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -14.7% | -18.8% |
| % Gain to Breakeven | 17.2% | 23.1% |
| Time to Breakeven | 64 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -18.4% | -9.5% |
| % Gain to Breakeven | 22.6% | 10.5% |
| Time to Breakeven | 45 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -13.3% | -6.7% |
| % Gain to Breakeven | 15.4% | 7.1% |
| Time to Breakeven | 71 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -24.8% | -24.5% |
| % Gain to Breakeven | 33.1% | 32.4% |
| Time to Breakeven | 813 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -25.9% | -33.7% |
| % Gain to Breakeven | 35.0% | 50.9% |
| Time to Breakeven | 32 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -12.6% | -19.2% |
| % Gain to Breakeven | 14.4% | 23.8% |
| Time to Breakeven | 37 days | 105 days |
In The Past
Danaher's stock fell -14.7% during the 2025 US Tariff Shock. Such a loss loss requires a 17.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | DHR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -24.8% | -24.5% |
| % Gain to Breakeven | 33.1% | 32.4% |
| Time to Breakeven | 813 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -25.9% | -33.7% |
| % Gain to Breakeven | 35.0% | 50.9% |
| Time to Breakeven | 32 days | 140 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -21.8% | -17.9% |
| % Gain to Breakeven | 27.8% | 21.8% |
| Time to Breakeven | 112 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -45.7% | -53.4% |
| % Gain to Breakeven | 84.1% | 114.4% |
| Time to Breakeven | 605 days | 1085 days |
In The Past
Danaher's stock fell -14.7% during the 2025 US Tariff Shock. Such a loss loss requires a 17.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Danaher (DHR)
Danaher Corporation (DHR) is a global diversified science and technology innovator that designs, manufactures, and markets a broad range of professional, medical, industrial, and commercial products and services. Its Life Sciences segment is a key driver, providing critical tools and technologies that support scientific research and biopharmaceutical development. This includes advanced instruments like mass spectrometers and microscopes, genomics consumables, lab automation, and bioprocess solutions for filtration and purification. These offerings are essential for pharmaceutical and biopharmaceutical companies, universities, research institutions, and various industrial manufacturers to advance drug discovery, development, and manufacturing.
Beyond life sciences research, Danaher’s Diagnostics segment focuses on enabling precise disease detection and patient management. It supplies hospitals, reference laboratories, and physician offices with a comprehensive suite of clinical instruments, reagents, and software for chemistry, immunoassay, microbiology, hematology, and pathology diagnostics. Completing its portfolio is the Environmental & Applied Solutions segment, which addresses vital industrial and commercial needs. This segment offers advanced instrumentation and disinfection systems for water analysis and and treatment across residential, commercial, and industrial applications, ensuring water quality. Additionally, it provides solutions for color and appearance management, as well as marking, coding, and traceability for packaging across consumer, pharmaceutical, and industrial products.
AI Analysis | Feedback
Here are 1-3 brief analogies for Danaher:
- Danaher is like the 'Intel Inside' for scientific and medical industries, providing the critical instruments, software, and consumables that power labs, hospitals, and biopharmaceutical manufacturing.
- Think of Danaher as a high-tech 3M, providing a diverse array of specialized instruments and solutions for scientific research, healthcare diagnostics, and environmental management.
AI Analysis | Feedback
- Life Sciences Instrumentation: Provides mass spectrometers, flow cytometers, microscopes, and related lab automation tools and consumables for research and development.
- Bioprocess Technologies: Offers technologies, consumables, and services for biopharmaceutical manufacturing, including filtration, separation, and purification.
- Diagnostics Systems: Supplies clinical instruments, reagents, and software for a broad range of diagnostic testing, including chemistry, immunoassay, microbiology, and pathology.
- Water Quality Management: Develops instrumentation, consumables, and disinfection systems for analyzing, treating, and managing water quality across various applications.
- Product Identification & Color Management: Provides instruments, software, and services for color and appearance management, packaging design, printing, marking, coding, and traceability.
AI Analysis | Feedback
Danaher (DHR) primarily sells its products and services to other companies and institutions. Based on the provided background, its major customers are broadly categorized as follows:
-
Pharmaceutical and Biopharmaceutical Companies: These companies rely on Danaher's life sciences tools, bioprocess technologies, genomics consumables, and gene/cell therapy solutions, as well as packaging and marking systems. Examples include Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK).
-
Healthcare Providers and Diagnostic Laboratories: This category includes hospitals, physicians' offices, reference laboratories, and other critical care settings that utilize Danaher's diagnostics systems, reagents, consumables, and services. Examples include Quest Diagnostics (DGX) and LabCorp (LH).
-
Academic and Research Institutions: Universities, medical schools, and research institutions are significant customers for Danaher's various life sciences instruments and consumables like mass spectrometers, microscopes, and lab automation. These are typically non-profit or government-funded entities and do not have stock symbols.
-
Industrial, Commercial, and Food & Beverage Companies: This broad group encompasses industrial manufacturers, food and beverage companies, consumer product companies, and commercial entities that rely on Danaher's environmental solutions for water analysis and treatment, as well as instruments for color and appearance management, packaging, printing, marking, and coding. Examples include PepsiCo (PEP) and various industrial manufacturing firms.
AI Analysis | Feedback
AI Analysis | Feedback
Rainer M. Blair, President and Chief Executive Officer
Rainer M. Blair has served as President and Chief Executive Officer of Danaher since September 2020 and has been a director since 2020. He joined Danaher in 2010 and held various leadership roles, including Executive Vice President of Danaher's Life Sciences platform from 2017 to September 2020 and Vice President–Group Executive from 2014 to 2017. Prior to joining Danaher, he was President and CEO of MAPEI Americas and held leadership positions with BASF Group across three continents. Mr. Blair is also a U.S. Army veteran and serves on Nestlé's board of directors.
Matthew M. McGrew, Executive Vice President and Chief Financial Officer
Matthew M. McGrew has served as Danaher's Executive Vice President and Chief Financial Officer since January 2019. He joined Danaher in 2004 as Director, M&A Finance and has held roles of increasing responsibility, including Vice President of Investor Relations from 2009 to 2014 and a Danaher Group CFO from 2012 to 2018. Prior to joining Danaher, Mr. McGrew was a director in the Transaction Services Group at KPMG. He is slated to step down from his CFO role effective February 28, 2026, and will continue as an Executive Vice President as he transitions to retirement.
Julie Sawyer Montgomery, Executive Vice President, Danaher Diagnostics Platform
Julie Sawyer Montgomery serves as the Executive Vice President of Danaher's Diagnostics Platform.
Greg Milosevich, Executive Vice President, Life Sciences
Greg Milosevich holds the position of Executive Vice President for Danaher's Life Sciences segment.
Chris Riley, Executive Vice President, Biotechnology Group and CEO, Cytiva
Chris Riley is the Executive Vice President of Danaher's Biotechnology Group and also serves as the CEO of Cytiva.
AI Analysis | Feedback
- High Capital Intensity, Debt, and Acquisition-Related Risks: Danaher is a capital-intensive business with significant capital needs and mounting debt levels, often used to finance acquisitions. There is a risk that acquisitions may not be successful, leading to increased debt and integration challenges. For example, the acquisition of Masimo has raised concerns about higher debt levels and integration risks.
- Declining Organic Revenue Growth and Profitability: The company has experienced declining organic revenue growth, suggesting that its core business may be underperforming due to decreasing demand. This trend could necessitate improvements in product offerings, pricing strategies, or market approaches. Additionally, Danaher has seen shrinking adjusted operating margins and a declining Return on Invested Capital (ROIC), indicating potential challenges in capital efficiency and overall profitability.
- Legal & Regulatory Risks and Governance Scrutiny: Danaher faces legal and regulatory risks, including the potential for changes in governmental regulations to reduce demand for its products or increase expenses. Furthermore, there is ongoing scrutiny, including investigations by law firms, into potential breaches of fiduciary duties by certain officers and directors, particularly concerning capital allocation decisions related to large acquisitions like Masimo. Such investigations can impact investor confidence in future mergers and acquisitions and overall governance.
AI Analysis | Feedback
The clear emerging threat for Danaher is the rapid advancement and adoption of **point-of-care (POC) testing and non-invasive diagnostic technologies** in the healthcare industry.
Danaher's Diagnostics segment primarily provides clinical instruments, reagents, consumables, software, and services for centralized laboratories, hospitals, and reference labs. This established model is increasingly challenged by highly accurate, comprehensive, and cost-effective diagnostic devices that can be used directly at the patient's bedside, in physicians' offices, or even at home, reducing the need for large, traditional lab setups.
This trend is analogous to how Apple's iPhone disrupted Research in Motion's BlackBerry by offering a more convenient and versatile platform that eventually rendered dedicated communication devices less appealing, or how Netflix's on-demand streaming model disrupted Blockbuster's physical rental business. Similarly, the ability to obtain diagnostic results quickly and conveniently at the point of care, or even through entirely non-invasive means, poses a direct threat to the demand for Danaher's core centralized lab diagnostic systems and associated consumables.
AI Analysis | Feedback
Addressable Markets for Danaher Corporation (DHR)
Danaher Corporation operates across three main segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions, each serving significant global markets.Life Sciences Segment
- Mass Spectrometry: The global mass spectrometry market size was estimated at USD 6.6 billion in 2024 and is projected to reach USD 10.65 billion by 2030. Another estimate places the global market at USD 8.17 billion in 2025, growing to approximately USD 17.75 billion by 2035.
- Flow Cytometry: The global flow cytometry market size was valued at USD 6.66 billion in 2025 and is projected to grow to USD 14.12 billion by 2034. Alternatively, the global market was accounted at USD 6.13 billion in 2025, expected to reach around USD 12.97 billion by 2035.
- Genomics: The global genomics market is projected to reach USD 85.09 billion by 2030 from USD 47.07 billion in 2025. Another forecast indicates the global genomics market size is expected to reach USD 175.18 billion by 2034, increasing from USD 44.21 billion in 2025. For genomics services specifically, the global market was valued at USD 9.80 billion in 2025 and is projected to grow to USD 30.85 billion by 2034.
- Lab Automation: The global laboratory automation market size was valued at USD 9.2 billion in 2025 and is projected to grow to USD 20.71 billion by 2034. Another report estimates the global lab automation market size at USD 8.36 billion in 2025, increasing to approximately USD 14.78 billion by 2034.
- Bioprocess Technologies: The global bioprocess technology market size was valued at USD 31.21 billion in 2024 and is estimated to reach USD 55.73 billion by 2033. Another source projects the global market to grow from USD 34.4 billion in 2025 to USD 141.5 billion by 2035.
- Gene and Cell Therapy Manufacturing: The global cell and gene therapy manufacturing market size was estimated at USD 21.15 billion in 2025 and is projected to hit around USD 215.18 billion by 2035. Another report indicates the global market will grow from USD 19.3 billion in 2024 to an estimated USD 146.2 billion by 2032.
- Pharmaceutical Filtration: The global pharmaceutical filtration market size is projected to grow from USD 13.21 billion in 2025 to USD 22.54 billion by 2032. Another source states the global market size was USD 13.64 billion in 2025, predicted to reach approximately USD 20.38 billion by 2034.
Diagnostics Segment
- In Vitro Diagnostics (IVD): The global in vitro diagnostics market size was estimated at USD 106.29 billion in 2025 and is projected to reach USD 128.18 billion by 2033. Other estimates for the global market include USD 77.73 billion in 2025, reaching USD 135.65 billion by 2034, USD 104.01 billion in 2025, reaching around USD 135.76 billion by 2035, and USD 122.6 billion in 2025, reaching USD 186.6 billion by 2034.
Environmental & Applied Solutions Segment
- Water Analysis Instrumentation: The global water analysis instrumentation market is projected to grow from USD 4.1 billion in 2025 to USD 7.1 billion by 2035. Another source indicates the global market size is estimated to reach over USD 8.20 billion by 2032 from a value of USD 4.78 billion in 2024. The global market size was also reported as USD 4.09 billion in 2026, reaching USD 6.37 billion by 2035.
- Color and Appearance Management (Software and Instruments): The global market for Color Management Software was estimated to be worth US$ 972 million in 2025 and is projected to reach US$ 1437 million by 2032. The global Color Management Comprehensive Measuring Instrument market was valued at USD 84.5 million in 2024 and is projected to reach USD 109 million by 2031.
- Product Identification, Marking, Coding, and Traceability: Null
AI Analysis | Feedback
Danaher Corporation (DHR) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- Strong Bioprocessing Segment Growth: Danaher anticipates high single-digit growth in its bioprocessing business, particularly fueled by continued strength in consumables and increasing demand for monoclonal antibodies and biosimilar production. This segment is consistently highlighted as a primary driver of overall revenue growth.
- Continuous Innovation and New Product Launches: The company is focused on accelerating investments in innovation, leading to the launch of several impactful new products and technologies across its Life Sciences and Diagnostics segments. Recent examples include the expansion of Cytiva's Xcellerex X-platform bioreactor, the introduction of SCIEX's ZenoTOF 8600 mass spectrometer, and the expansion of Beckman Coulter Diagnostics' immunoassay platform. New product revenue has recently contributed significantly to growth.
- Strategic Acquisitions: Danaher has a proven track record of strategic acquisitions to enhance its portfolio, expand into attractive markets, and acquire companies with strong market positions and recurring revenue streams. Management views the M&A environment as more constructive, with a strong balance sheet ready for strategic acquisitions. Recent notable acquisitions include Masimo, expected to be accretive and enhance growth and margins.
- Improving Momentum in Diagnostics and Life Sciences End Markets: While some areas faced challenges, Danaher expects a gradual improvement in its broader Diagnostics and Life Sciences end markets. This includes sustained growth in non-respiratory Cepheid revenue, with particular strength in areas like sexual health and virology assays, driven by increasing menu adoption and system utilization, as well as geographic expansion opportunities.
AI Analysis | Feedback
Share Repurchases
- Danaher's annual share buybacks totaled $5.979 billion in 2024.
- In 2025, annual share buybacks for Danaher amounted to $3.088 billion.
- The trailing twelve months (TTM) annual share buybacks for DHR stock were $772 million.
Outbound Investments
- Danaher announced plans in February 2026 to acquire Masimo Corporation for an enterprise value of $9.9 billion, with the deal projected to close in the second half of 2026.
- In 2023, Danaher completed the acquisition of Abcam for approximately $5.7 billion.
- Danaher invested $9.6 billion in the acquisition of Aldevron in 2021.
Capital Expenditures
- Danaher's capital expenditures for fiscal year 2024 reached a peak of $1.392 billion.
- Capital expenditures for fiscal year 2025 were $1.156 billion.
- From fiscal years 2021 to 2025, Danaher's capital expenditures averaged $1.258 billion annually.
Peer Outperformance in Life Sciences Tools & Services
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 8.6% | 52.6% | 97.9% | CAH 468% · MCK 380% · COR 183% |
| Health Care Services | 20 | 40.1% | 49.1% | 16.2% | HIMS 271% · RDNT 137% · DGX 86% |
| Health Care Facilities | 25 | 1.3% | 24.8% | 0.5% | THC 274% · NHC 254% · EHC 152% |
| Managed Health Care | 8 | 26.0% | -1.0% | -4.3% | OSCR 78% · HQY 54% · ELV 3% |
| Health Care Equipment | 50 | -3.3% | 13.8% | -18.1% | UFPT 358% · GKOS 297% · PLSE 160% |
| Pharmaceuticals | 61 | -16.2% | 9.8% | -32.5% | LQDA 1113% · KNSA 770% · LLY 432% |
| Health Care Supplies | 11 | 19.3% | 1.8% | -38.4% | LNTH 337% · HAE 76% · MMSI 36% |
| Life Sciences Tools & Services ← | 107 | -7.5% | 8.2% | -65.2% | NTRA 262% · AXGN 226% · MEDP 215% |
| Biotechnology | 365 | -22.5% | -17.6% | -80.0% | DNTH 1140% · ELVN 1127% · TRVI 1107% |
| Health Care Technology | 21 | -30.9% | -55.8% | -82.1% | VEEV 1% · DOCS -51% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Danaher stock vs Agilent Technologies stock: Which Is A Better Investment? | 08/05/2026 | |
| Reading Between The Lines Of DHR's Latest Call | 07/24/2026 | |
| Danaher Earnings Notes | 07/18/2026 | |
| Danaher Stock Now 3.8% Cheaper, Time To Buy | 12/16/2025 | |
| How Low Can Danaher Stock Really Go? | 10/17/2025 | |
| DHR Leadership & 32% Price Drop - Time to Buy? | 10/15/2025 | |
| Now Is Not The Time To Buy Danaher Stock | 10/04/2025 | |
| ARTICLES | ||
| S&P 500 Movers | Winners: ACN, SNPS, FICO | Losers: PSKY, MKC, DHR | 10/02/2026 | |
| Reading Between The Lines Of DHR’s Latest Call | 07/24/2026 | |
| S&P 500 Movers | Winners: SNDK, WDC, MU | Losers: DHR, MSCI, TYL | 07/22/2026 | |
| How Will Danaher Stock React To Its Upcoming Earnings? | 07/20/2026 | |
| TMO, IQV Look Smarter Buy Than Danaher Stock | 06/25/2026 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 216.74 |
| Mkt Cap | 110.3 |
| Rev LTM | 24,429 |
| Op Inc LTM | 4,281 |
| FCF LTM | 4,118 |
| FCF 3Y Avg | 4,004 |
| CFO LTM | 5,060 |
| CFO 3Y Avg | 4,988 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.6% |
| Rev Chg 3Y Avg | 3.6% |
| Rev Chg Q | 8.9% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Inc Chg LTM | 10.7% |
| Op Inc Chg 3Y Avg | 6.3% |
| Op Mgn LTM | 19.1% |
| Op Mgn 3Y Avg | 17.2% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 21.5% |
| CFO/Rev 3Y Avg | 20.8% |
| FCF/Rev LTM | 17.0% |
| FCF/Rev 3Y Avg | 17.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 110.3 |
| P/S | 6.1 |
| P/Op Inc | 31.2 |
| P/EBIT | 29.1 |
| P/E | 38.1 |
| P/CFO | 26.7 |
| Total Yield | 3.3% |
| Dividend Yield | 0.6% |
| FCF Yield 3Y Avg | 3.7% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.5% |
| 3M Rtn | 21.9% |
| 6M Rtn | 44.9% |
| 12M Rtn | 26.9% |
| 3Y Rtn | 47.1% |
| 1M Excs Rtn | 3.7% |
| 3M Excs Rtn | 17.8% |
| 6M Excs Rtn | 36.3% |
| 12M Excs Rtn | 13.2% |
| 3Y Excs Rtn | -47.8% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Diagnostics | 9,941 | 9,787 | 9,577 | 10,849 | 9,844 |
| Life Sciences | 7,334 | 7,329 | 7,141 | 7,036 | 6,388 |
| Biotechnology | 7,293 | 6,759 | 7,172 | 8,758 | 8,570 |
| Other | 0 | 0 | 0 | 0 | |
| Total | 24,568 | 23,875 | 23,890 | 26,643 | 24,802 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Diagnostics | 2,650 | 2,625 | 2,406 | 3,436 | 2,313 |
| Biotechnology | 1,864 | 1,685 | 1,909 | 3,008 | 3,074 |
| Life Sciences | 520 | 879 | 1,209 | 1,414 | 1,293 |
| Other | -344 | -326 | -322 | -322 | -303 |
| Total | 4,690 | 4,863 | 5,202 | 7,536 | 6,377 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Biotechnology | 37,337 | 34,605 | 37,421 | 37,536 | 38,118 |
| Life Sciences | 23,112 | 23,211 | 23,730 | 17,572 | 19,768 |
| Diagnostics | 14,748 | 14,204 | 14,552 | 14,722 | 15,054 |
| Other | 8,267 | 5,522 | 8,785 | 9,739 | 5,407 |
| Discontinued operations | 4,781 | 4,837 | |||
| Total | 83,464 | 77,542 | 84,488 | 84,350 | 83,184 |
Price Behavior
| Market Price | $234.07 | |
| Market Cap ($ Bil) | 164.7 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -2.7% | |
| 50 Days | 200 Days | |
| DMA Price | $217.80 | $200.48 |
| DMA Trend | up | indeterminate |
| Distance from DMA | 7.5% | 16.8% |
| 3M | 1YR | |
| Volatility | 28.5% | 30.1% |
| Downside Capture | 2.48 | 35.22 |
| Upside Capture | 97.23 | 37.83 |
| Correlation (S&P 500) | 21.7% | 19.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.97 | 0.55 | -0.22 | 0.04 | 0.42 | 0.77 |
| Up Beta | 1.02 | -0.55 | -0.87 | -0.15 | 0.30 | 0.90 |
| Down Beta | 1.64 | 1.32 | -0.54 | 0.58 | 0.74 | 0.82 |
| Up Capture | 107% | 118% | 37% | 11% | 32% | 26% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 11 | 23 | 35 | 66 | 127 | 386 |
| Down Capture | 52% | 10% | -56% | -39% | 32% | 89% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 11 | 19 | 29 | 60 | 125 | 366 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DHR | |
|---|---|---|---|---|
| DHR | 6.7% | 30.1% | 0.22 | - |
| Sector ETF (XLV) | 24.5% | 16.3% | 1.15 | 48.8% |
| Equity (SPY) | 13.7% | 12.7% | 0.72 | 18.6% |
| Gold (GLD) | 1.8% | 28.3% | 0.05 | 5.8% |
| Commodities (DBC) | 48.4% | 20.6% | 1.80 | -22.3% |
| Real Estate (VNQ) | 2.8% | 13.9% | -0.05 | 24.9% |
| Bitcoin (BTCUSD) | -29.4% | 43.4% | -0.68 | 8.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DHR | |
|---|---|---|---|---|
| DHR | -3.0% | 29.2% | -0.09 | - |
| Sector ETF (XLV) | 8.3% | 15.2% | 0.34 | 64.1% |
| Equity (SPY) | 12.7% | 17.1% | 0.56 | 51.7% |
| Gold (GLD) | 17.5% | 18.9% | 0.74 | 7.3% |
| Commodities (DBC) | 9.1% | 19.5% | 0.35 | 2.5% |
| Real Estate (VNQ) | 0.6% | 18.9% | -0.08 | 48.3% |
| Bitcoin (BTCUSD) | 4.1% | 51.6% | 0.26 | 18.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DHR | |
|---|---|---|---|---|
| DHR | 13.8% | 26.3% | 0.51 | - |
| Sector ETF (XLV) | 11.7% | 16.7% | 0.57 | 67.6% |
| Equity (SPY) | 15.5% | 17.9% | 0.73 | 58.1% |
| Gold (GLD) | 12.0% | 16.4% | 0.60 | 7.2% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 9.9% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 47.1% |
| Bitcoin (BTCUSD) | 62.3% | 66.2% | 1.02 | 13.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 10/29/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/21/2026 | -1.8% | 0.1% | |
| 7/21/2026 | -11.0% | -2.3% | -0.8% |
| 4/21/2026 | -0.5% | -7.6% | -14.6% |
| 1/28/2026 | -4.8% | -8.1% | -11.2% |
| 10/21/2025 | 5.9% | 6.1% | 8.2% |
| 7/22/2025 | 1.0% | 7.9% | 12.8% |
| 4/22/2025 | 3.8% | 5.9% | 6.9% |
| 1/29/2025 | -9.7% | -13.2% | -17.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 13 | 12 |
| # Negative | 13 | 12 | 12 |
| Median Positive | 3.7% | 5.9% | 8.2% |
| Median Negative | -3.5% | -6.4% | -9.6% |
| Max Positive | 9.1% | 10.4% | 14.9% |
| Max Negative | -11.0% | -13.2% | -17.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/21/2026 | -1.8% | 0.1% | |
| 7/21/2026 | -11.0% | -2.3% | -0.8% |
| 4/21/2026 | -0.5% | -7.6% | -14.6% |
| 1/28/2026 | -4.8% | -8.1% | -11.2% |
| 10/21/2025 | 5.9% | 6.1% | 8.2% |
| 7/22/2025 | 1.0% | 7.9% | 12.8% |
| 4/22/2025 | 3.8% | 5.9% | 6.9% |
| 1/29/2025 | -9.7% | -13.2% | -17.0% |
| 10/22/2024 | -4.0% | -10.3% | -15.2% |
| 7/23/2024 | 5.3% | 8.3% | 8.3% |
| 4/23/2024 | 7.2% | 4.5% | 12.9% |
| 1/30/2024 | 4.7% | 5.1% | 9.3% |
| 10/24/2023 | -3.5% | -9.3% | 6.8% |
| 7/25/2023 | -0.9% | -1.1% | -3.2% |
| 4/25/2023 | -8.8% | -5.0% | -9.6% |
| 1/24/2023 | -2.0% | -5.1% | -9.7% |
| 10/20/2022 | -5.7% | -1.6% | 0.7% |
| 7/21/2022 | 9.1% | 9.4% | 14.9% |
| 4/21/2022 | -0.8% | -10.0% | -11.1% |
| 1/27/2022 | 1.2% | 10.4% | 4.7% |
| 10/21/2021 | -1.3% | -3.0% | -0.7% |
| 7/22/2021 | 3.3% | 4.7% | 14.3% |
| 4/22/2021 | 3.5% | 5.7% | 4.3% |
| 1/28/2021 | 2.9% | 7.2% | -1.1% |
| 10/22/2020 | 3.3% | 2.4% | -0.3% |
| SUMMARY STATS | |||
| # Positive | 12 | 13 | 12 |
| # Negative | 13 | 12 | 12 |
| Median Positive | 3.7% | 5.9% | 8.2% |
| Median Negative | -3.5% | -6.4% | -9.6% |
| Max Positive | 9.1% | 10.4% | 14.9% |
| Max Negative | -11.0% | -13.2% | -17.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 10/21/2026 | 10-Q |
| 06/30/2026 | 07/21/2026 | 10-Q |
| 03/31/2026 | 04/21/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/21/2025 | 10-Q |
| 06/30/2025 | 07/22/2025 | 10-Q |
| 03/31/2025 | 04/22/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 10/22/2024 | 10-Q |
| 06/30/2024 | 07/23/2024 | 10-Q |
| 03/31/2024 | 04/23/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 10/24/2023 | 10-Q |
| 06/30/2023 | 07/25/2023 | 10-Q |
| 03/31/2023 | 04/25/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 10/21/2026 | 10-Q |
| 06/30/2026 | 07/21/2026 | 10-Q |
| 03/31/2026 | 04/21/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/21/2025 | 10-Q |
| 06/30/2025 | 07/22/2025 | 10-Q |
| 03/31/2025 | 04/22/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 10/22/2024 | 10-Q |
| 06/30/2024 | 07/23/2024 | 10-Q |
| 03/31/2024 | 04/23/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 10/24/2023 | 10-Q |
| 06/30/2023 | 07/25/2023 | 10-Q |
| 03/31/2023 | 04/25/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 10/20/2022 | 10-Q |
| 06/30/2022 | 07/21/2022 | 10-Q |
| 03/31/2022 | 04/21/2022 | 10-Q |
| 12/31/2021 | 02/23/2022 | 10-K |
| 09/30/2021 | 10/21/2021 | 10-Q |
| 06/30/2021 | 07/22/2021 | 10-Q |
| 03/31/2021 | 04/22/2021 | 10-Q |
| 12/31/2020 | 02/25/2021 | 10-K |
| 09/30/2020 | 10/22/2020 | 10-Q |
| 06/30/2020 | 07/23/2020 | 10-Q |
| 03/31/2020 | 05/06/2020 | 10-Q |
| 12/31/2019 | 02/21/2020 | 10-K |
Insider Activity
Updated 10/14/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blair, Rainer | President & CEO | Trust | Sell | 8242026 | 218.63 | 58,255 | Form | ||
| 2 | Spoon, Alan G | Direct | Sell | 5042026 | 174.67 | 1,358 | 237,207 | 21,675,904 | Form | |
| 3 | Milosevich, Gregory M | Executive Vice President | Direct | Sell | 2202026 | 208.01 | 1,320 | 274,575 | 1,060,648 | Form |
| 4 | Rales, Mitchell P | Chairman of Exec. Committee | Through the Mitchell P. Rales Family Trust | Sell | 11262025 | 230.38 | 40,625 | 9,359,067 | 195,820,472 | Form |
| 5 | List, Teri | Direct | Sell | 11192025 | 226.50 | 3,298 | 746,997 | 4,702,592 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blair, Rainer | President & CEO | Trust | Sell | 8242026 | 218.63 | 58,255 | Form | ||
| 2 | Spoon, Alan G | Direct | Sell | 5042026 | 174.67 | 1,358 | 237,207 | 21,675,904 | Form | |
| 3 | Milosevich, Gregory M | Executive Vice President | Direct | Sell | 2202026 | 208.01 | 1,320 | 274,575 | 1,060,648 | Form |
| 4 | Rales, Mitchell P | Chairman of Exec. Committee | Through the Mitchell P. Rales Family Trust | Sell | 11262025 | 230.38 | 40,625 | 9,359,067 | 195,820,472 | Form |
| 5 | List, Teri | Direct | Sell | 11192025 | 226.50 | 3,298 | 746,997 | 4,702,592 | Form | |
| 6 | Ellis, Brian W | Senior Vice President - GC | Direct | Sell | 11132025 | 219.23 | 21,776 | 4,773,863 | 3,190,394 | Form |
| 7 | Rales, Mitchell P | Chairman of Exec. Committee | Direct | Sell | 11132025 | 218.69 | 437,000 | 95,566,167 | 120,983,705 | Form |
| 8 | McGrew, Matthew | EVP & Chief Financial Officer | Direct | Sell | 11132025 | 214.62 | 16,172 | 3,470,831 | 4,305,702 | Form |
| 9 | Couchara, Georgeann | SVP, Human Resources | Direct | Sell | 11112025 | 210.42 | 5,174 | 1,088,704 | 552,348 | Form |
| 10 | Rales, Mitchell P | Chairman of Exec. Committee | Direct | Sell | 11042025 | 216.06 | 600,000 | 129,636,027 | 213,948,706 | Form |
Investor Activity (13F)
Updated Oct 29, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Generation Investment Management LLP | $1.4 Bil | 12.4% | 29 | Hold | 13F |
| Defender Capital, LLC. | $29.9 Mil | 10.6% | 34 | Hold | 13F |
| Dorsey Asset Management, LLC | $110.0 Mil | 8.8% | 11 | TRIM -29.9% | 13F |
| Anomaly Capital Management, LP | $144.6 Mil | 8.8% | 21 | ADD +119.3% | 13F |
| Arvin Capital Management LP | $35.2 Mil | 8.2% | 23 | ADD +35.9% | 13F |
| 11 Capital Partners LP | $23.0 Mil | 7.5% | 19 | ADD +7.4% | 13F |
| Two Creeks Capital Management, LP | $67.4 Mil | 7.1% | 21 | ADD +33.0% | 13F |
| Weitz Investment Management, Inc. | $90.6 Mil | 6.3% | 49 | TRIM -7.0% | 13F |
| Manchester Global Management (UK) Ltd | $43.7 Mil | 5.8% | 23 | Hold | 13F |
| Consulta Ltd | $113.8 Mil | 5.7% | 13 | Hold | 13F |
| Spear Holdings RSC Ltd | $52.9 Mil | 5.7% | 17 | New | 13F |
| PBCay One RSC Ltd | $52.9 Mil | 5.7% | 17 | New | 13F |
| Palestra Capital Management LLC | $128.5 Mil | 5.0% | 22 | Hold | 13F |
| Third Point LLC | $99.5 Mil | 4.8% | 33 | TRIM -12.5% | 13F |
| L1 Capital International Pty Ltd | $75.1 Mil | 4.5% | 23 | Hold | 13F |
| Highlander Partners, L.P. | $11.0 Mil | 4.3% | 47 | New | 13F |
| Coalescence Partners Investment Management, LP | $18.5 Mil | 4.0% | 12 | Hold | 13F |
| D1 Capital Partners L.P. | $436.9 Mil | 3.9% | 44 | ADD +311.7% | 13F |
| BlueSpruce Investments, LP | $24.1 Mil | 3.8% | 10 | TRIM -79.8% | 13F |
| Dudley & Shanley, Inc. | $21.8 Mil | 3.6% | 38 | Hold | 13F |
| Milestones Administradora de Recursos Ltda. | $13.3 Mil | 3.5% | 17 | ADD +62.2% | 13F |
| Spinecap SAS | $9.4 Mil | 3.4% | 15 | Hold | 13F |
| Castle Hook Partners LP | $166.8 Mil | 3.4% | 44 | TRIM -23.6% | 13F |
| Generali Powszechne Towarzystwo Emerytalne | $17.3 Mil | 3.1% | 28 | Hold | 13F |
| M.D. Sass, LLC | $38.1 Mil | 2.9% | 36 | TRIM -34.0% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Southpoint Capital Advisors LP | $113.8 Mil | 2.3% | 41 | New | 13F |
| Eminence Capital, LP | $106.4 Mil | 2.4% | 33 | New | 13F |
| Gates Foundation Trust | $70.7 Mil | 0.2% | 22 | New | 13F |
| Spear Holdings RSC Ltd | $52.9 Mil | 5.7% | 17 | New | 13F |
| PBCay One RSC Ltd | $52.9 Mil | 5.7% | 17 | New | 13F |
| Woodbridge Co Ltd | $19.7 Mil | 0.1% | 46 | New | 13F |
| Highlander Partners, L.P. | $11.0 Mil | 4.3% | 47 | New | 13F |
| Capco Asset Management, LLC | $8.4 Mil | 2.3% | 27 | New | 13F |
| D1 Capital Partners L.P. | $436.9 Mil | 3.9% | 44 | ADD +311.7% | 13F |
| Anomaly Capital Management, LP | $144.6 Mil | 8.8% | 21 | ADD +119.3% | 13F |
| Milestones Administradora de Recursos Ltda. | $13.3 Mil | 3.5% | 17 | ADD +62.2% | 13F |
| Arvin Capital Management LP | $35.2 Mil | 8.2% | 23 | ADD +35.9% | 13F |
| Two Creeks Capital Management, LP | $67.4 Mil | 7.1% | 21 | ADD +33.0% | 13F |
| Skye Global Management LP | $47.0 Mil | 1.0% | 44 | ADD +26.5% | 13F |
| Unisphere Establishment | $121.2 Mil | 1.0% | 50 | ADD +12.3% | 13F |
| Mar Vista Investment Partners LLC | $22.8 Mil | 2.3% | 35 | ADD +12.3% | 13F |
| 11 Capital Partners LP | $23.0 Mil | 7.5% | 19 | ADD +7.4% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| Tri Locum Partners LP | $79.4 Mil | 10.3% | 15 | Exited | Dec 31, 2025 | 13F |
| Cartenna Capital, LP | $60.7 Mil | 3.2% | 36 | Exited | Dec 31, 2025 | 13F |
| Saraza Management, LP | $17.2 Mil | 6.7% | 15 | Exited | Dec 31, 2025 | 13F |
| Napean Trading & Investment Co (Singapore) PTE Ltd | $13.7 Mil | 2.7% | 37 | Exited | Dec 31, 2025 | 13F |
| Archon Partners LLC | $9.2 Mil | 1.0% | 42 | Exited | Dec 31, 2025 | 13F |
| Cooper Investors PTY LTD | $7.0 Mil | 2.3% | 41 | Exited | Dec 31, 2025 | 13F |
| BlueSpruce Investments, LP | $24.1 Mil | 3.8% | 10 | TRIM -79.8% | Mar 31, 2026 | 13F |
| Owl Creek Asset Management, L.P. | $6.6 Mil | 1.3% | 21 | TRIM -45.4% | Mar 31, 2026 | 13F |
| M.D. Sass, LLC | $38.1 Mil | 2.9% | 36 | TRIM -34.0% | Mar 31, 2026 | 13F |
| Blue Whale Capital LLP | $29.2 Mil | 1.4% | 26 | TRIM -32.1% | Mar 31, 2026 | 13F |
| Dorsey Asset Management, LLC | $110.0 Mil | 8.8% | 11 | TRIM -29.9% | Mar 31, 2026 | 13F |
| Castle Hook Partners LP | $166.8 Mil | 3.4% | 44 | TRIM -23.6% | Mar 31, 2026 | 13F |
| Glenview Capital Management, LLC | $29.6 Mil | 0.8% | 41 | TRIM -21.9% | Mar 31, 2026 | 13F |
| Third Point LLC | $99.5 Mil | 4.8% | 33 | TRIM -12.5% | Mar 31, 2026 | 13F |
| Weitz Investment Management, Inc. | $90.6 Mil | 6.3% | 49 | TRIM -7.0% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Generation Investment Management LLP | $1.4 Bil | 12.4% | 29 | Hold | 13F |
| D1 Capital Partners L.P. | $436.9 Mil | 3.9% | 44 | ADD +311.7% | 13F |
| Mirova US LLC | $199.4 Mil | 2.3% | 42 | Hold | 13F |
| Castle Hook Partners LP | $166.8 Mil | 3.4% | 44 | TRIM -23.6% | 13F |
| Anomaly Capital Management, LP | $144.6 Mil | 8.8% | 21 | ADD +119.3% | 13F |
| Palestra Capital Management LLC | $128.5 Mil | 5.0% | 22 | Hold | 13F |
| Unisphere Establishment | $121.2 Mil | 1.0% | 50 | ADD +12.3% | 13F |
| Consulta Ltd | $113.8 Mil | 5.7% | 13 | Hold | 13F |
| Southpoint Capital Advisors LP | $113.8 Mil | 2.3% | 41 | New | 13F |
| Dorsey Asset Management, LLC | $110.0 Mil | 8.8% | 11 | TRIM -29.9% | 13F |
| Eminence Capital, LP | $106.4 Mil | 2.4% | 33 | New | 13F |
| Third Point LLC | $99.5 Mil | 4.8% | 33 | TRIM -12.5% | 13F |
| Weitz Investment Management, Inc. | $90.6 Mil | 6.3% | 49 | TRIM -7.0% | 13F |
| L1 Capital International Pty Ltd | $75.1 Mil | 4.5% | 23 | Hold | 13F |
| Gates Foundation Trust | $70.7 Mil | 0.2% | 22 | New | 13F |
| Two Creeks Capital Management, LP | $67.4 Mil | 7.1% | 21 | ADD +33.0% | 13F |
| Spear Holdings RSC Ltd | $52.9 Mil | 5.7% | 17 | New | 13F |
| PBCay One RSC Ltd | $52.9 Mil | 5.7% | 17 | New | 13F |
| Skye Global Management LP | $47.0 Mil | 1.0% | 44 | ADD +26.5% | 13F |
| Manchester Global Management (UK) Ltd | $43.7 Mil | 5.8% | 23 | Hold | 13F |
| M.D. Sass, LLC | $38.1 Mil | 2.9% | 36 | TRIM -34.0% | 13F |
| Arvin Capital Management LP | $35.2 Mil | 8.2% | 23 | ADD +35.9% | 13F |
| Defender Capital, LLC. | $29.9 Mil | 10.6% | 34 | Hold | 13F |
| Glenview Capital Management, LLC | $29.6 Mil | 0.8% | 41 | TRIM -21.9% | 13F |
| Blue Whale Capital LLP | $29.2 Mil | 1.4% | 26 | TRIM -32.1% | 13F |
DHR Trade Sentinel
Constructive
CONVICTION RATIONALE
Core growth ex-respiratory accelerated for a third straight quarter to 5.5%. A new CEO is focused on commercial execution, supported by a strong leading indicator of mid-teens order growth in the critical bioprocessing business. While execution must be proven, the company also raised its full-year 2026 adjusted EPS guidance to $8.57-$8.62.
STOCK ARCHETYPE
Instruments & Consumables (Razor/Blade)(Installed Base of Instruments * Utilization Rate * Price per Consumable) + (New Instrument Sales * Price per Instrument) Operating margin expansion driven by the application of the Danaher Business System (DBS) for continuous cost and process improvement, and operating leverage from growth in high-margin recurring consumables revenue.
INVESTMENT THESIS
Evidence points to a successful re-acceleration, with core growth inflecting positively and key leading indicators suggesting continued momentum into 2027.
- Core revenue growth ex-respiratory accelerated to 5.5% in Q3 2026.
- Bioprocessing orders grew at a 'mid-teens' rate in Q3 2026.
- Full-year 2026 adjusted EPS guidance was raised to $8.57-$8.62.
- Operating margin expanded to 20.4% on a trailing-twelve-month basis.
- Basic share count has fallen 4.8% over the last three years.
PRIMARY RISK
Despite improving end markets, core growth of 5.5% still trails key peers. A significant inventory build, growing 8.9 percentage points faster than revenue, suggests a potential mismatch with demand that could pressure future margins if the recovery falters or share gains do not materialize.
- Q3 core growth of 5.5% trailed a peer's 6% organic growth.
- Inventory grew 8.9 percentage points faster than revenue in Q3.
- Diagnostics segment saw price decreases of 1.0% in Q3 2026.
- Q4 core growth ex-respiratory is guided to 4.0%-5.0%, a sequential slowdown.
| KPI | Status | Rationale |
|---|---|---|
| Core Revenue Growth Excluding Respiratory Revenue | 5.5% year-over-year growth for Q3 2026 - Accelerating | The company's underlying growth has shown consistent acceleration throughout the year, which management attributes to improving end-market conditions and strong execution. The latest quarter's 5.5% growth represents a 100 basis point acceleration from the second quarter. |
| Biotechnology Segment Core Revenue Growth | 5.0% year-over-year core revenue growth for Q3 2026 - Turning around | The segment's growth slowed in Q2 due to what management described as a shift in shipment timing for a few large commercial customers. The Q3 growth of 5.0% indicates a recovery. Importantly, bioprocessing orders, a leading indicator, grew at a robust mid-teens rate in both Q2 and Q3, suggesting strong underlying demand. |
| Latest-Quarter Revenue Growth (Y/Y) | 8.3% (Q3 2026) | Indicates the year-over-year growth rate of the company's total revenue, reflecting overall demand and business momentum. |
| Inventory vs. Revenue Growth Divergence | 8.9 percentage points (Q3 2026) | Shows that inventory grew 8.9 percentage points faster than revenue in the latest quarter, which can be a leading indicator of slowing demand or potential future margin pressure if inventory needs to be written down. |
| Bioprocessing Orders Growth | mid-teens (Q3 2026) | Indicates future revenue potential for the bioprocessing business, a key part of the Biotechnology segment. Strong order growth suggests healthy underlying demand from pharma and biotech customers. |
New CEO Execution vs. Lagging Peer Growth
BULL VIEW
Bulls believe the new CEO's focus on commercial execution, combined with strong mid-teens bioprocessing order growth, will enable Danaher to close the growth gap with peers and take market share in a recovering end market.
CORE TENSION
Can strong bioprocessing orders and a new execution focus overcome the fact that Q3 core growth (5.5%) still lags peers (6.0% and 7.3%)?
PREVAILING SENTIMENT
The latest evidence favors the bulls. The mid-teens order growth is a strong leading indicator, and management raised the full-year 2026 EPS guidance, signaling operational confidence.
BEAR VIEW
Bears argue the recent acceleration is just a cyclical market lift, not share gains, pointing to Q3 core growth of 5.5% that still trails competitors. The high inventory build suggests the recovery could be fragile.
| Timeline | Event & Metric To Watch |
|---|---|
October 30, 2026 | Quarterly Dividend Payment Watch: A quarterly cash dividend of $0.40 per share is scheduled to be paid. |
November 2026 | Inherited Masimo Litigation Watch: Rulings, settlements, or new disclosures from arbitration and court hearings related to the acquired Masimo business. |
November 2026 | Masimo Arbitration Hearing Watch: A hearing is scheduled for an arbitration proceeding involving acquired company Masimo and Willow Laboratories, Inc. |
11/23/2026 | China Market Headwinds Watch: Peer commentary on China's volume-based procurement, reimbursement policies, and overall demand trends in life sciences and diagnostics. |
December 17, 2026 | Masimo Litigation Hearing Watch: A hearing is scheduled for a motion for summary judgment in litigation involving acquired company Masimo. |
1/20/2027 | Peer Earnings Report Watch: Peer Abbott Laboratories (ABT) is scheduled to report earnings. |
1/26/2027 | Respiratory Season Underperformance Watch: Q4 respiratory revenue results versus guidance and management's outlook for the next season. |
1/26/2027 | Quarterly Earnings Release Watch: Danaher is scheduled to report its next quarterly earnings and provide a detailed guidance outlook. |
1/27/2027 | Peer Earnings Report Watch: Peer Thermo Fisher Scientific (TMO) is scheduled to report earnings. |
No set date | New CEO Strategy Execution Watch: Progress on commercial execution initiatives, evidence of cross-selling synergies, and any changes to capital allocation priorities. |
| Date | Event | Stock Impact |
|---|---|---|
2026-10-14 | NVIDIA Collaboration Announced Details: The company announced a collaboration with NVIDIA to advance autonomous science by combining NVIDIA's AI technologies with Danaher's scientific instruments and laboratory workflows. | +3.9% $222.84 -> $231.50 |
2026-10-07 | AI-Powered Autonomous Lab Announced Details: Danaher announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster. | +0.9% $215.61 -> $217.46 |
2026-08-03 | New CEO Appointed Details: The Board of Directors appointed Julie Sawyer Montgomery as President and Chief Executive Officer, effective October 1, 2026, following the retirement of Rainer Blair. | -0.1% $194.64 -> $194.44 |
2026-07-21 | Q2 Earnings and Guidance Update Details: The company reported Q2 revenue of $6.3 billion, up 5.5% year-over-year, and raised full-year EPS guidance. However, guidance for 2026 Core Revenue Growth was lowered. | -10.9% $200.75 -> $178.82 |
2026-06-10 | Masimo Acquisition Completed Details: Danaher completed its acquisition of Masimo Corporation, a provider of pulse oximetry and patient monitoring solutions, primarily in acute care settings. | -4.0% $187.69 -> $180.10 |
2026-04-22 | Q1 Earnings Reported Details: The company reported first-quarter 2026 sales of $6.0 billion, with core revenue up 0.5% year-over-year, as strength in bioprocessing offset a lighter-than-normal respiratory season. | -8.2% $193.79 -> $177.89 |
Position Sizing
4% - 6%
NORMAL POSITION
Sizing is volatility-based: DHR trades at roughly 31% annualized realized (three-month) volatility versus about 11% for the S&P 500 (2.8x the market). A 4% - 6% position keeps a single-name swing of that size within a diversified portfolio's risk budget.
Diversification Alternatives
TMO - Thermo Fisher Scientific
Broadest Life-Sciences ExposureThermo Fisher offers greater scale with revenue 1.8 times larger than Danaher's and a more diversified portfolio, potentially providing more stability. However, its gross margin of 40.8% is significantly lower.
A - a business partner
Analytical Lab LeaderAgilent provides more concentrated exposure to the analytical instruments market. Its Q3 core revenue growth of 7.3% outpaced Danaher's, suggesting strong momentum in its specific end markets.
A holding company of leading life science and diagnostic franchises, driven by a rigorous operational playbook (the Danaher Business System) and a disciplined M&A strategy.
Danaher's value is created by acquiring leading science and technology companies and then applying its proprietary Danaher Business System (DBS) to drive continuous improvement, operational excellence, and margin expansion. The new CEO is focusing on strengthening commercial execution and creating a more 'connected Danaher' to better leverage the breadth of the portfolio. The company is also investing in AI to enhance innovation and internal productivity.
Sustained acceleration in core revenue growth, unambiguous market share gains, successful integration of acquisitions like Masimo, and margin expansion from DBS initiatives.
Failure to accelerate core growth, market share losses to competitors, margin erosion due to pricing pressure or cost inflation, or unsuccessful capital deployment.
Minor quarterly fluctuations in respiratory testing revenue or single-customer order timing shifts.
Repricing Catalyst
Successful execution of the new CEO's strategy to drive commercial excellence and a more connected sales approach, leading to accelerated core growth and share gains.
Biotechnology
$7.5B TTM (30% of Total) · 26% MarginWhat It Is
Sells equipment, consumables, software, and services used to research, develop, manufacture, and deliver biological medicines. Customers include pharmaceutical and biopharmaceutical companies, biotechnology companies, and contract manufacturing organizations.
Who Pays & How
Pharmaceutical and biotech companies pay for tools and services that advance and integrate the development and manufacturing of therapeutics, including protein-based therapies, cell and gene therapies, and vaccines. They choose Danaher for product quality, reliability, and the ability to enhance productivity.
Competition
Life Sciences
$7.5B TTM (30% of Total) · 14% MarginWhat It Is
Sells instruments, consumables, services, and software used to study the basic building blocks of life (DNA, RNA, proteins, cells). Customers include pharmaceutical and biotech companies, universities, medical schools, and research institutions.
Who Pays & How
Research, scientific, and medical professionals pay for tools that enable the discovery, development, and manufacture of new therapies. They select products based on quality, reliability, and the capacity to enhance productivity and innovation.
Competition
Diagnostics
$10.1B TTM (40% of Total) · 25% MarginWhat It Is
Sells clinical instruments, consumables, software, and services used to diagnose disease and make treatment decisions. Customers include hospitals, physicians' offices, reference laboratories, and other critical care settings.
Who Pays & How
Hospitals, labs, and physicians pay for diagnostic testing systems that provide accurate and rapid results to guide patient care. They choose products based on quality, reliability, accuracy, speed, and total cost of ownership.
Competition
Danaher — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.